Subscribe

Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM)

USD32.75 -0.37 (-1.12%)
NASDAQ USD US Equity
NAV USD 33.02 -0.82% vs NAV as of 2026-07-13
AUM USD 63.73M
TER 0.59%
Yield (TTM) 1.25%
Distribution Distributing · Irregular
52-week range 23.47 – 37.01
Holdings 27
Issuer Roundhill Investments

About this ETF

Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.

ISIN US77926X8829
Issuer Roundhill Investments
Domicile US
Inception 2024-05-21
Asset class Equity

Price

Top 10 holdings

Novo Nordisk A/S NVO 13.12%
Eli Lilly & Co LLY 12.32%
Pfizer Inc PFE 6.28%
CSPC Pharmaceutical Group Ltd 1093.HK 6.05%
Viking Therapeutics Inc VKTX 5.72%
Kailera Therapeutics Inc KLRA 5.72%
Ascletis Pharma Inc 1672.HK 4.34%
Chugai Pharmaceutical Co Ltd 4519.T 4.33%
Amgen Inc AMGN 3.78%
Zealand Pharma A/S ZEAL.CO 3.74%
See full holdings →